The authors of "Primary Open-Angle Glaucoma Suspect Preferred Practice Pattern®" (*Ophthalmology*. 2021;128:P151-P192) would like to note the following corrections:



The following references should have been cited after reference 189 in the following sentence on P169: Other glaucoma medications include, alpha<sub>2</sub> adrenergic agonists, parasympathomimetics, rho-kinase inhibitors, and topical and oral carbonic anhydrase inhibitors.<sup>188,189</sup>

- Serle JB, Katz LJ, McLaurin E, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116-127.
- Khouri AS, Serle JB, Bacharach J, et al. Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: The Randomized Phase 3 ROCKET-4 Study. Am J Ophthalmol. 2019;204:97-104.
- 3. Bacharach J, Dubiner HB, Levy B, et al. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. *Ophthalmology*. 2015;122:302-307.
- 4. Kahook MY, Serle JB, Mah FS, et al. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. *Am J Ophthalmol.* 2019;200:130-137.

Drug Classification	Agents	Methods of Action	IOP Reduction*	Potential Side Effects	Potential Contraindications	FDA Pregnancy Safety Category†
Rho kinase inhibitors	Netarsudil Increase trabecular outflow Decrease episcleral venous pressure Decrease aqueous production		15%-25%	<ul> <li>Conjunctival hyperemia</li> <li>Corneal verticillata</li> <li>Instillation site pain</li> <li>Conjunctival hemorrhage</li> <li>Keratitis</li> </ul>	• None	_**

Table 2: The 5th row and footnote should have appeared as follows (correction in boldface):

\*Data from the Heijl A, Traverso CE, eds. Terminology and Guidelines for Glaucoma. European Glaucoma Society. 5th ed. Savona, Italy: PubliComm; 2020: (In Press at the time of this publication). Accessed at https://www.eugs.org/eng/guidelines.asp